Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. [A transition from targeting immune evasion to a multidisciplinary collaborative treatment framework for "homotherapy for heteropathy" in liver metastases].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
   Review
2. PET/CT-based quantification of intratumoral heterogeneity for predicting pathological complete response in breast cancer patients treated with neoadjuvant chemotherapy: A multicentre study.European journal of nuclear medicine and molecular imaging · 2026
   Article
3. A Retrospective Observational Study of Safety and Effectiveness of Abemaciclib in Chinese Patients with Breast Cancer.Advances in therapy · 2026
   Observational
4. Omission of completion axillary dissection in clinically node-negative breast cancer with 1-2 metastatic sentinel lymph nodes.World journal of surgical oncology · 2026
   Article
5. St. Gallen International Breast Cancer Consensus-Based Clinical Decision Validation: Concordance Assessment Between Deep Large Language Model Outputs and Global Expert Panel Recommendations.Annals of surgical oncology · 2026
   Article
6. Balancing global standards and regional nuances in breast cancer care: the role of guidelines, clinical research, precision medicine, and artificial intelligence in advancing quality of care for patients worldwide.Cancer biology & medicine · 2026
   Article
7. Research progress on immune tolerance mechanisms in liver metastatic tumors and the "Liver-metastasis-oriented shared-mechanism therapeutic strategy" approach.Medical review (2021) · 2026
   Review
8. Triple-negative breast cancer survival outcomes: prognostic model validated with SEER database.Discover oncology · 2026
   Article
9. Sequential CDK4/6 inhibition in bone-only metastatic HR+/HER2- breast cancer: a case of prolonged disease control with abemaciclib after clinical progression on palbociclib-based therapy.Frontiers in medicine · 2026
   Article
10. Trends, survival and regional control of sentinel lymph node biopsy versus axillary dissection in cN0 breast cancer: a multicenter cohort in China.Frontiers in oncology · 2026
    Article
11. Progression-free survival exceeding four years after transarterial embolization for liver metastases from triple-negative breast cancer: a case report.Frontiers in oncology · 2026
    Article
12. Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study.Breast cancer (Dove Medical Press) · 2026
    Article
13. Rare advanced complication of an infusion port with pocket skin necrosis successfully preserve the port : a case report.Journal of cardiothoracic surgery · 2025
    Article
14. Axillary fat metastasis in breast cancer: A case report.Oncology letters · 2025
    Article
15. Ginkgo ketone ester tablets for the treatment of cognitive impairment associated with chemotherapy for breast cancer - a prospective cohort study.Frontiers in pharmacology · 2025
    Article
16. DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
    Article
17. Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer.Cancer cell international · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.